To perform an economical evaluation of darunavir + low-dose ritonavir (DR) vs other protease inhibitors (PIs) in treatment-experienced HIV-1-infected patients in the Russian health care system. METHODS: The modeled study was performed. A proportion of patients receiving alternative PIs, dosing regimen, and efficacy of drugs were extracted from multicenter randomized studies POWER 1 and 2 (Lancet 2007; 369:1169-78). The effect was measured in proportion of patients with viral load reduction of 1 log 10 copies/ml or greater from baseline and with viral load less than 50 copies/ml. Other PIs in POWER studies were lopinavir + ritonavir, saquinavir, amprenavir, atazanavir, indinavir, nelfinavir; all patients in both groups received optimized background regimen. Cost of treatment with PIs for 48 weeks and cost-effectiveness ratio (CER) were calculated from the Russian reimbursement system point of view. RESULTS: According to POWER studies, DR was much more effective than other PIs (61 vs 15% of patients had viral load reduction Ն1 log 10 copies/ml and 45 vs 10% achieved viral load <50 copies/ml), while cost of treatment was a little more for DR than other PIs (370,786.08 vs. 330,747.59 rubles or 15,105.64 vs USD 13,474.47). Incremental CER was 87,000 rubles (USD 3544.34) for one patient with viral load reduction Ն1 log 10 copies/ml and 114,400 rubles (USD 4660.60) for one patient with viral load <50 copies/ml that seems reasonable for expensive antiHIV treatment. CONCLUSION: According to the model, DR seems to be much more effective than other PIs with affordable CER incremental ratio. Evaluation of DR treatment effectiveness and safety in common practice is needed.
PIN20 PHARMACOECONOMICS OF CHRONIC HEPATITIS B AND HEPATITIS C
Freiberga M, Ageichenko V,Vegeris I, Babarykin D Medical Consulting Service Ltd, Riga, Latvia OBJECTIVE: Globally, an estimated 170 million persons are chronically infected with hepatitis C virus (HNV) and 350 million-with hepatitis B (HBV). New HCV and HBV medicines are 100%-400% more costly and have a negative impact on the budget. The aim of this study was to calculate, in the health care payer perspective, the cost effectiveness (CE) of new medicines for HCV and HBV treatment in comparison with the previous generation ones. METHODS: This analysis compares the CE of entecavir, adefovir dipivoxil versus lamivudinum in previous therapy refractory HBV patients and the CE of peginterferonum alfa with interferonum alfa in chronic HCV patients. 
